- Home
- TRTX vs REPL Comparison
TRTX vs REPL Comparison
Compare TRTX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRTX
- REPL
- Stock Information
- Founded
- TRTX 2014
- REPL 2015
- Country
- TRTX United States
- REPL United States
- Employees
- TRTX N/A
- REPL 479
- Industry
- TRTX Real Estate Investment Trusts
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- TRTX Real Estate
- REPL Health Care
- Exchange
- TRTX Nasdaq
- REPL Nasdaq
- Market Cap
- TRTX 708.3M
- REPL 721.7M
- IPO Year
- TRTX 2017
- REPL 2018
- Fundamental
- Price
- TRTX $8.80
- REPL $9.42
- Analyst Decision
- TRTX Buy
- REPL Buy
- Analyst Count
- TRTX 3
- REPL 9
- Target Price
- TRTX $10.75
- REPL $12.00
- AVG Volume (30 Days)
- TRTX 557.6K
- REPL 2.6M
- Earning Date
- TRTX 10-28-2025
- REPL 11-06-2025
- Dividend Yield
- TRTX 10.90%
- REPL N/A
- EPS Growth
- TRTX N/A
- REPL N/A
- EPS
- TRTX 0.65
- REPL N/A
- Revenue
- TRTX $138,590,000.00
- REPL N/A
- Revenue This Year
- TRTX N/A
- REPL N/A
- Revenue Next Year
- TRTX $6.62
- REPL N/A
- P/E Ratio
- TRTX $13.60
- REPL N/A
- Revenue Growth
- TRTX 4.13
- REPL N/A
- 52 Week Low
- TRTX $6.47
- REPL $2.68
- 52 Week High
- TRTX $9.85
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- TRTX 46.36
- REPL 62.38
- Support Level
- TRTX $8.68
- REPL $8.50
- Resistance Level
- TRTX $8.89
- REPL $9.30
- Average True Range (ATR)
- TRTX 0.16
- REPL 0.61
- MACD
- TRTX -0.02
- REPL -0.14
- Stochastic Oscillator
- TRTX 25.85
- REPL 75.95
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.